Maze Therapeutics (MAZE) Research & Development (2024 - 2026)

Maze Therapeutics has reported Research & Development for 3 years, with the latest figure at $34.1 million in Q1 2026.

• Quarterly Research & Development rose 23.81% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.0 million (up 28.94% YoY) and the FY2025 annual result came in at $108.4 million, up 29.88% from the prior year.
• Research & Development rose to $34.1 million in Q1 2026 per MAZE's latest filing, from $27.6 million in the prior quarter.
• Over five years, Research & Development peaked at $34.1 million in Q1 2026 and troughed at $19.5 million in Q2 2024.
• A 3-year average of $25.1 million and a median of $25.2 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2025 and 2026: Research & Development jumped 43.8% in 2025, then increased 23.81% in 2026.
• Over 3 years, Research & Development stood at $22.2 million in 2024, then grew by 24.1% to $27.6 million in 2025, then climbed by 23.86% to $34.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $34.1 million, $27.6 million, and $25.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.